Drug Profile

LEM S401

Alternative Names: LEM-S401; siRNA encapsulated in DegradaBALL^®

Latest Information Update: 11 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lemonex
Class Gene therapies; Skin disorder therapies; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Hypertrophic scars; Keloids

Most Recent Events

03 Feb 2023 Lemonex completes a phase I trial in Hypertrophic-scar keloid (In volunteers) in South Korea (SC, Injection) (NCT04707131)
31 Aug 2022 Phase-I clinical trials in Hypertrophic scars (In volunteers) in South Korea (SC) (NCT04707131) (Lemonex pipeline, December 2022)
31 Aug 2022 Phase-I clinical trials in Keloids (In volunteers) in South Korea (SC) (NCT04707131) (Lemonex pipeline, December 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com